Myeloma Master Class

This educational series is designed to provide insights and guidance
on the critical and challenging issues in multiple myeloma.
More information coming soon

MYSummit Myeloma Conference October 7-9, 2021

MYELOMA360 is pleased to announce our first annual MYSummit Conference
October 7-9, 2021 in Edinburgh, UK

Ask the Experts

You have questions. Our Expert Panel responds.

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

News

Daratumumab Monotherapy Demonstrates Efficacy in R/R Myeloma

Daratumumab Monotherapy Demonstrates Efficacy in R/R Myeloma

A recent article published Feb. 2, 2021 in the Annals of Hematology demonstrated efficacy and safety of daratumumab (DARA) monotherapy in real-world patients. The GIMEMA Lazio group reported experience in 62 patients with relapsed/ refractory myeloma who had...

read more
Selected Journal Articles for the Week of January 18th

Selected Journal Articles for the Week of January 18th

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice Background: We have performed a head to head comparison of all-oral triplet...

read more
Melflufen Plus Dexamethasone in RRMM Shows Durable Response

Melflufen Plus Dexamethasone in RRMM Shows Durable Response

Updated survival data for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy was published in the British Journal of Haematology. The...

read more
Oncopeptides Enrolls 1st Patient in Phase 3 LIGHTHOUSE Study

Oncopeptides Enrolls 1st Patient in Phase 3 LIGHTHOUSE Study

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab...

read more

Featured Content

Join Our Community

By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions. 
Of course, you can opt out at any time.